For 40 years, bone cancer in children had no new treatment. A Cleveland team may have found one.

The treatment for osteosarcoma has barely changed since the Reagan administration. For 40 years, the protocol has been the same: chemotherapy, surgery, more chemotherapy. Survival rates for localized disease have improved, but for patients whose cancer has spread - roughly 20% of new diagnoses - the prognosis remains grim, and the options have remained stubbornly limited.

Osteosarcoma is the most common type of bone cancer in children and young adults, striking primarily during periods of rapid bone growth. About 1,000 new cases are diagnosed in the United States each year. The disease appears to originate from DNA changes in bone-forming cells, and while its exact cause is unknown, its peak incidence during adolescence implicates the cellular activity of growth itself.

A study from Case Western Reserve University and University Hospitals, published in BMC Medicine, presents what may be the first viable immunotherapy approach for this disease: a specially engineered CAR-T cell therapy called OSM CAR-T.

Why solid tumors have defeated CAR-T

CAR-T (Chimeric Antigen Receptor T-cell) therapy works by extracting a patient's T cells, genetically reprogramming them to recognize specific molecular markers on cancer cells, then infusing the modified cells back into the patient's bloodstream. The approach has transformed treatment for blood cancers - certain leukemias and lymphomas now have CAR-T therapies with remarkable response rates.

Solid tumors have been a different story. The National Cancer Institute notes that cancer cells in solid tumors display a more heterogeneous array of surface markers than blood cancers. Different cells within the same tumor can express different proteins on their surfaces, making it difficult for CAR-T cells that target a single marker to eliminate every cancer cell. The tumor microenvironment also actively suppresses immune responses, creating a hostile landscape for engineered T cells.

Targeting the oncostatin M receptor

The breakthrough in this study lies in the choice of target. Lead researcher Reshmi Parameswaran, associate professor at the Case Western Reserve School of Medicine and scientist at UH Seidman Cancer Center, identified receptors for a protein called oncostatin M (OSM) that appear on the surface of osteosarcoma cells. Rather than targeting a single surface marker, the OSM CAR-T cells recognize multiple receptor components, allowing them to identify cancer cells through several recognition points simultaneously.

This multi-receptor targeting strategy addresses the heterogeneity problem that has plagued other solid tumor CAR-T approaches. Even if some cancer cells express lower levels of one receptor component, the engineered T cells can still recognize and attack them through other receptor variants on the same cell surface.

Results across patient samples and metastatic models

The OSM CAR-T cells showed anti-tumor effects against all osteosarcoma patient samples tested in the laboratory. That breadth of activity across different patient tumors is encouraging, since osteosarcoma is genetically diverse and treatments that work against one patient's tumor often fail against another's.

The metastatic disease results may be the most significant. Tumor cells that have spread to other organs represent the greatest clinical challenge in osteosarcoma - they are the primary reason patients die, and they are largely resistant to existing chemotherapy regimens. In mouse models with metastatic osteosarcoma, OSM CAR-T cells were effective at killing tumor cells that had spread to distant organs.

Mouse models, clinical horizon

These are preclinical results in mouse models and laboratory cell cultures, not human clinical trials. The path from a promising mouse study to an approved therapy is long and uncertain. Many immunotherapy approaches that show dramatic results in mice fail to replicate those results in humans, where the tumor microenvironment, immune system complexity, and dosing challenges are all more formidable.

The research team anticipates that clinical trials could begin within two years. If the therapy proves effective and safe in humans, it could offer a targeted treatment option that harnesses the patient's own immune system against the cancer - potentially reducing the reliance on the intensive chemotherapy regimens that carry their own substantial toxicities.

For patients with metastatic osteosarcoma, who currently have few effective options, even a modest advance would be meaningful. The possibility of a therapy that specifically targets metastatic cells - the ones that existing treatments fail to control - addresses the most lethal aspect of the disease.

The study was made possible by the collaborative research infrastructure at Case Western Reserve's Comprehensive Cancer Center and University Hospitals, which provided the specialized facilities for developing and testing engineered immune cell therapies against solid tumors.